Quantcast

Latest Access Pharmaceuticals Inc. Stories

2014-08-14 08:30:20

Company Strengthens Intellectual Property Protection in Additional Global Market DALLAS and NEW YORK, Aug. 14, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, has received notification from the Japan Patent Office that a patent for MuGard and ProctiGard has been granted. The patent covers a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders. "Following our recent European...

2014-07-30 08:33:42

DALLAS and NEW YORK, July 30, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a developer of new products for oncology supportive care, announced that its novel product for oral mucositis, MuGard(®), has been featured in an article on OncLive.com titled, "Study Finds Mouth Rinse Alleviates Oral Mucositis Symptoms in Head and Neck Cancers." Dr. Steve Sonis, a leading expert in oral mucositis, provides insight on the growing demand seen in the oncology community for...

2014-07-22 08:32:06

New product offers treatment to significant unmet medical need in supportive cancer care DALLAS and NEW YORK, July 22, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a developer of new products for oncology supportive care, announced today that it has received 510(K) marketing clearance from the U.S. Food and Drug Administration (FDA) for ProctiGard(TM), its novel treatment for symptomatic management of rectal mucositis. The Company indicated its development of...

2014-07-08 12:28:56

Company Continues Reinforcing Intellectual Property Protection in Additional Global Markets DALLAS and NEW YORK, July 8, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, has received notification from the Hong Kong Patent Office that a patent for MuGard(TM) has been granted. The patent (HK1126134) protects a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders. "Being awarded...

2014-05-01 08:31:31

NEW YORK, May 1, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that the data from its multi-institutional post-approval trial of MuGard(®) that was recently published in Cancer, has been selected as a cover article in the premier publication. Cancer, the journal of the American Cancer Society is one of the oldest peer-reviewed journals in oncology. The publication, entitled "Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to Assess...

2014-04-15 08:30:20

NEW YORK, April 15, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that positive results from a study conducted at Nova Southeastern University were presented recently at the Frontiers in Oral Medicine 2014 conference, hosted by the American Academy of Oral Medicine, in Orlando, Florida. The poster, entitled "Effectiveness of a Polymer-Based Muco-Adhesive (MuGard(®)) in the Healing of Oral Ulcers in Erosive Lichen...

2014-04-08 08:32:03

Additional Mucoadhesive Polymer Hydrogel Technology Formulation; Seeking Marketing Partners NEW YORK, April 8, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard(TM), for the treatment of inflammatory and ulcerative conditions of the esophagus. Amlexanox is a novel anti-inflammatory and anti-allergic agent that has been approved and used in the US, Japan and other countries,...

2014-04-01 08:29:19

Expanding Product Offerings; Building IP Portfolio; Seeking Global Marketing Partners NEW YORK, April 1, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided investors with a strategic update on its programs and plans for its proprietary mucoadhesive hydrogel platform technology. Access' patented technology surrounds a unique aqueous pseudoplastic liquid with a defined viscosity range, which is beneficial to the treatment of disorders of mucosal tissue, and...

2014-03-26 08:29:22

Company Seeking Global Marketing Partners for its Proprietary Vitamin B-12 Drug Delivery Technology NEW YORK, March 26, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that it is leveraging its proprietary CobaCyte(TM) drug delivery platform technology to create new formulations of active pharmaceutical agents. Access recently submitted an additional patent application to protect improvements in the technology and...

2014-03-21 08:25:00

Leveraging Proprietary Mucoadhesive Polymer Hydrogel Technology to Expand Product Offerings; Seeking Global Marketing Partners NEW YORK, March 21, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that it has advanced development of a new proprietary product, called ProctiGard(TM), for the treatment of radiation proctitis. Radiation proctitis ("RP") is a significant unmet medical need, with no well-established standard of care. It is estimated that there are...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'